Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors

Sub-indication: Miscellaneous Malignancies

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Trishula Therapeutics, Inc.

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.